{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:15:42Z","timestamp":1783041342929,"version":"3.54.6"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.anndiagpath.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T22:22:17Z","timestamp":1547677337000},"page":"42-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Fatty acid synthase, Her2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Aziza E.","family":"Abdelrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayam E.","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Elkady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Elsebai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Azony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anndiagpath.2019.01.002_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0010","first-page":"5","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.anndiagpath.2019.01.002_bb0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14737140.2018.1432358","article-title":"Current approaches for identifying high-risk non-muscle invasive bladder cancer","volume":"18","author":"Sanli","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0025","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0030","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3892\/mmr.2016.4902","article-title":"Overexpression of fatty acid synthase predicts a poor prognosis for human gastric cancer","volume":"13","author":"Duan","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.7150\/ijbs.7357","article-title":"Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells","volume":"10","author":"Li","year":"2014","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11060-014-1452-z","article-title":"Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis","volume":"118","author":"Grube","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0045","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3892\/mmr.2015.4746","article-title":"Downregulation of fatty acid synthase complex suppresses cell migration by targeting phospho-AKT in bladder cancer","volume":"13","author":"Zheng","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0050","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/01635581.2012.701704","article-title":"Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K\/Akt signaling pathway","volume":"64","author":"Li","year":"2012","journal-title":"Nutr Cancer"},{"issue":"7","key":"10.1016\/j.anndiagpath.2019.01.002_bb0055","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1194\/jlr.M036103","article-title":"Nutrient-dependent phosphorylation channels lipid synthesis to regulate PPAR","volume":"54","author":"Jensen-Urstad","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/jcp.2010.076570","article-title":"A study of HER2 gene amplification and protein expression in gastric cancer","volume":"63","author":"Yan","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0065","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbrc.2009.05.085","article-title":"Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells","volume":"385","author":"Grunt","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0070","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3892\/ol.2015.3609","article-title":"A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients","volume":"10","author":"Li","year":"2015","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.anndiagpath.2019.01.002_bb0075","first-page":"743","article-title":"Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer","volume":"8","author":"Kim","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2017.00311","article-title":"E2F1. A novel regulator of metabolism","volume":"8","author":"Denechaud","year":"2017","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0085","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/0008-5472.CAN-11-2575","article-title":"The dark side of E2F1: in transit beyond apoptosis","volume":"72","author":"Engelmann","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0090","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","article-title":"Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2019.01.002_bb0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2019.01.002_bb0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0105","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non- muscle- invasive urothelial carcinoma of thebladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0110","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1158\/0008-5472.CAN-11-4057","article-title":"Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer","volume":"72","author":"Zaytseva","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/2278-330X.173164","article-title":"Human epidermal growth factor receptor 2\/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: is it worth hype?","volume":"4","author":"Kumar","year":"2015","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12253-016-0043-z","article-title":"E2F1\/TS immunophenotype and survival of patients with colorectal cancer treated with 5FU-based adjuvant therapy","volume":"22","author":"Sulzyc-Bielicka","year":"2016","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0130","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/carcin\/bgu042","article-title":"Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer","volume":"35","author":"Zaytseva","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0135","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.bjc.6605007","article-title":"De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy","volume":"100","author":"Mashima","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0140","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1210\/jc.2008-0503","article-title":"Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers","volume":"93","author":"Uddin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.anndiagpath.2019.01.002_bb0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1476-511X-12-83","article-title":"Loss of fatty acid synthase inhibits the \u201cHER2-PI3K\/Akt axis\u201d activity and malignant phenotype of Caco-2 cells","author":"Li","year":"2013","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.01.002_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2012.02.046","article-title":"Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer","volume":"80","author":"Jiang","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6890-14-3","article-title":"Increased fatty acid synthase expression in prostate biopsy cores predicts higher Gleason score in radical prostatectomy specimen","volume":"14","author":"Hamada","year":"2014","journal-title":"BMC Clin Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2019.01.002_bb0160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00795-010-0517-0","article-title":"Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients","volume":"44","author":"Sugino","year":"2011","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12032-014-0391-z","article-title":"Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer","volume":"32","author":"Cai","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0170","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1517\/13543784.16.11.1817","article-title":"Fatty acid synthase inhibitors: new directions for oncology","volume":"16","author":"Kridel","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.anndiagpath.2019.01.002_bb0180","article-title":"Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma","volume":"7","author":"Gelebart","year":"2012"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0185","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/00365599.2011.637955","article-title":"HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder","volume":"46","author":"Olsson","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","article-title":"Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression","volume":"66","author":"Chen","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmau.2013.06.001","article-title":"Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression","volume":"1","author":"Charfia","year":"2013","journal-title":"J Microsc Ultrastruct"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0210","first-page":"277","article-title":"Clinical significance of Her2\/neu overexpression in urothelial carcinomas","volume":"51","author":"Alexai","year":"2010","journal-title":"Romanian J Morphol Embryol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2019.01.002_bb0215","first-page":"457","article-title":"Prognostic impact of HER2\/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research","volume":"14","author":"Skagias","year":"2009","journal-title":"J BUON"},{"issue":"1","key":"10.1016\/j.anndiagpath.2019.01.002_bb0220","first-page":"137","article-title":"EGFR and Her2\/neu immunoexpression in papillary urothelial bladder carcinomas","volume":"54","author":"Enache","year":"2013","journal-title":"Rom J Morphol Embryol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2019.01.002_bb0225","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0230","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/bcr2777","article-title":"Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells","volume":"12","author":"Jin","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0235","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.oraloncology.2007.06.008","article-title":"ErbB2 and fatty acid synthase (FAS) expression in 102 squamous cell carcinomas of the tongue: correlation with clinical outcomes","volume":"44","author":"Silva","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0240","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.2010.05777.x","article-title":"Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer","volume":"1210","author":"Oliveras","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.anndiagpath.2019.01.002_bb0245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1101\/gad.864201","article-title":"E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis","volume":"15","author":"Muller","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0255","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ncb868","article-title":"Direct coupling of the cell cycle and cell death machinery by E2F","volume":"4","author":"Nahle","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.anndiagpath.2019.01.002_bb0260","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nature02820","article-title":"Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control","volume":"430","author":"Hernando","year":"2004","journal-title":"Nature"},{"issue":"7635","key":"10.1016\/j.anndiagpath.2019.01.002_bb0265","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36","volume":"541","author":"Pascual","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.anndiagpath.2019.01.002_bb0270","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI81542","article-title":"E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis","volume":"126","author":"Denechaud","year":"2016","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.anndiagpath.2019.01.002_bb0275","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/onc.2010.454","article-title":"Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma","volume":"30","author":"Bhatia","year":"2011","journal-title":"Oncogene"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913418303678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913418303678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:30:22Z","timestamp":1761078622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913418303678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":55,"alternative-id":["S1092913418303678"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.01.002","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid synthase, Her2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}